Vaccination

Studies Show Continued Efficacy of New UTI Vaccine

Retrieved on: 
星期六, 五月 4, 2024
UTI, Vaccination, Interview, Woman, American Urological Association, Abstract (summary), Abstract, MD, Urology, Research, Urinary tract infection, Urogynecology, Communication, Infection, Annual general meeting, SAN, Female, Northwell Health

SAN ANTONIO, May 04, 2024 (GLOBE NEWSWIRE) -- Abstracts being presented at the American Urological Association's Annual Meeting discuss a new urinary tract infection (UTI) treatment as well as the UTI implications of weight management drugs.

Key Points: 
  • SAN ANTONIO, May 04, 2024 (GLOBE NEWSWIRE) -- Abstracts being presented at the American Urological Association's Annual Meeting discuss a new urinary tract infection (UTI) treatment as well as the UTI implications of weight management drugs.
  • Researchers will present their study findings covering important updates on UTI in San Antonio, Texas, from May 3 to 6.
  • “Fifty percent of women develop a urinary tract infection in their lifetime and a quarter will experience recurrent infections.
  • Treating this can be challenging for the patient and for providers,” said Dr. Lee.

Microneedle Flu Vaccine Market Research 2024 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - ResearchAndMarkets.com

Retrieved on: 
星期五, 五月 3, 2024
Pharmaceutical, Health, Medical Supplies, USD, Mortality, Public, Vaccination, Pandemic, Fear, Influenza, Risk, Measles, Skin, Infection, Iontophoresis, Research, Sonophoresis, Vaccine, Disease, Patient, Marketing, Season, Drug development, Anxiety, Viral, COVID-19, Injection

The "Microneedle Flu Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microneedle Flu Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F" report has been added to ResearchAndMarkets.com's offering.
  • Global Microneedle Flu Vaccine Market was valued at USD 1.10 Billion in 2023 and is anticipated to grow with a CAGR of 5.89% through 2029.
  • Expanding the vaccine portfolio beyond seasonal influenza vaccines opens up new revenue streams for manufacturers and developers in the microneedle vaccine market.
  • Based on the Vaccine Type segment, the Trivalent Flu Vaccine segment has been the dominant force in the market.

International Decade of Sciences for Sustainable Development Forum opens in Beijing

Retrieved on: 
星期日, 四月 28, 2024
Online, Education, United Nations, UNAM, AIDS, Research, Sustainable development, Science policy, Policy, Culture, TWAS, Non-governmental organization, Private sector, Vaccination, Research fellow, Information technology, Republic, Club, United Nations General Assembly, UN, Infection, Artificial intelligence, Engineering, Multimedia, Natural science, Division, Big data, CAPRISA, UNGA, CRI, HIV/AIDS, Environment, Sustainable Development Goals, Ministry, UNESCO, Quarantine, COVID-19, Management

BEIJING, April 28, 2024 /PRNewswire/ -- A news report from CRI Online:

Key Points: 
  • BEIJING, April 28, 2024 /PRNewswire/ -- A news report from CRI Online:
    In August 2023, the United Nations General Assembly (UNGA) adopted the resolution "International Decade of Sciences for Sustainable Development 2024-2033" (Sciences Decade).
  • UNESCO, in collaboration with the Ministry of Science and Technology of the People's Republic of China and the People's Government of Beijing Municipality, co-organized the "International Decade of Sciences for Sustainable Development Forum" on April 25, Beijing, China.
  • The primary objective of the International Decade of Sciences for Sustainable Development Forum is to foster a culture of science by expanding the outreach of the Science Decade, engaging with the scientific community, government entities, the private sector, and civil societies on the vision and mission of the Decade, and mobilizing various stakeholders for its effective implementation.
  • The Science Decade echoes the annual theme of the 2024 ZGC Forum, "Innovation: Building a Better World", and further demonstrates the internationalization of the ZGC Forum.

EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Retrieved on: 
星期五, 五月 3, 2024
University, Part, CMO, Federal republic, Research, Cancer, Federal Patent Court (Germany), Vaccine, Business, Webcast, BioNTech, District court, Whole genome sequencing, Vaccination, Public, WHO, Hearing loss, Cardiology, Animal, EP 1, Omicron, GSK, Systems biology, Workforce, Infection, Messenger, Federal court, Therapy, Data monitoring committee, Safety, Monroe Dunaway Anderson, CVAC, Justice, RNA, Astrocytoma, Motion, Human, CureVac, Pandemic, GMP, Sąd rejonowy, SARS-CoV-2, Business development, Epitope, MD, Acuitas Therapeutics, DSMB, Ageing, Patent, Patient, Neurology, Operating cost, H5N1, MD Anderson Cancer Center, PPA, Interim, MBA, Antigen, COVID-19, Amgen

ET / 3 p.m. CET

Key Points: 
  • ET / 3 p.m. CET
    TÜBINGEN, Germany/BOSTON, USA – April 24, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the fourth quarter and full-year 2023 and provided a business update.
  • “We closed out 2023 on a sturdy footing and are poised to advance strongly through 2024 with strategic initiatives to make CureVac fit-for-purpose.
  • Thaminda Ramanayake was appointed to the CureVac Management Team as Chief Business Officer effective June 1, 2024.
  • Mr. Ramanayake joins CureVac from Affini-T Therapeutics, where he served as Chief Business Officer and was responsible for creating the company’s business development organization.

EQS-News: DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTENT ANTIGEN PRESENTATION

Retrieved on: 
星期五, 五月 3, 2024
Vaccination, DTC, Microsoft Exchange Server, Mouse, OTCQB, Animal, Male, Protein, Unfolded protein response, Female, Disturbance, Antigen presentation, Toxicity, Melanoma, Therapy, Cancer, Vaccine

The use of AccuTOX® to reprogram these MSCs relies mainly on the induction of protein aggregation.

Key Points: 
  • The use of AccuTOX® to reprogram these MSCs relies mainly on the induction of protein aggregation.
  • In addition, our team found that at specific doses, AccuTOX® forms protein aggregates when mixed with tumor lysate, a process that pushes MSCs to degrade these intracellular complexes resulting in potent antigen presentation."
  • The ARM-002TM vaccine is even more potent, as it actually requires 10x less protein.
  • These results will set the target indication for the Phase I trials, and it also shows how versatile and adaptable the ARM-002TM anti-cancer vaccine is.

Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award

Retrieved on: 
星期五, 四月 19, 2024
Education, Science, Mentorship, MenAfriVac, Death, Vaccine, Life, Government, Rising Star Award, Klugman, Basta, Global health, Vaccination, Public, Diarrhea, Neonatal sepsis, Princeton University, Developing country, SAMRC, Meningococcal vaccine, Gold medal, DRS, Child, McGill University, RSV, Tomer Capone, Infection, National academy, Pneumonia, Pregnancy, Publication, Health, Research, Meningococcal disease, Sabin Vaccine Institute, Gold, Rotavirus, Student, Organization, GBS, University of the Witwatersrand, University, Canada Research Chair, Florida Department, CBE, Policy, Fever Dream, Disease, Meningitis, HPV, COVID-19

Fueled by an early interest in science as a child in South Africa -- in part due to a physician father – Klugman holds both a medical as well as a science doctorate degree from Wits University and was the first student in the school’s history to obtain them simultaneously. He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist. Klugman is widely known for his work on pneumonia, which still kills a child under five every 43 seconds, many in the world’s poorest countries. As the director of the pneumonia program at the Seattle-based Bill and Melinda Gates Foundation, Klugman orchestrates strategic initiatives aimed at reducing deaths from pneumonia, RSV, neonatal sepsis, and meningitis. He has authored hundreds of publications that have been cited over 50,000 times to date and has been elected to the National Academy of Medicine in the United States. Klugman is also a professor emeritus of global health at Atlanta’s Emory University.

Key Points: 
  • Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute.
  • He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist.
  • His scientific achievements aside, Klugman has long championed the need for the world’s poorest children to have equitable access to vaccines.
  • Sabin’s Rising Star award was created in 2020 to encourage and recognize the next generation of vaccine and immunization leaders.

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

Retrieved on: 
星期一, 四月 15, 2024
Momentum, Vaccination, CMS, Risk, Safety, SARS-CoV-2, Food, Health care, Pre-exposure prophylaxis, Patient, COVID-19, Immunodeficiency, Medicare, Interim, HCPCS, Pharmaceutical industry

In addition, CMS issued a product specific M code (M0224) covering the administration of PEMGARDA.

Key Points: 
  • In addition, CMS issued a product specific M code (M0224) covering the administration of PEMGARDA.
  • Both HCPCS codes are effective retroactively to March 22, 2024, the date of emergency use authorization (EUA) for PEMGARDA.
  • HCPCS is a group of standardized codes that represent medical procedures, supplies, products, and services.
  • For additional information about PEMGARDA, please see the full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning.

Global Home Infusion Therapy Market Analysis, Trends and Forecasts 2023-2028: Soaring Demand for At-Home Chronic Disease Management, Emerging Potential in Chemotherapy - ResearchAndMarkets.com

Retrieved on: 
星期四, 四月 25, 2024
Health, Medical Supplies, Medical Devices, Conditional sentence, Disability, Vaccination, Administration, Cancer, Route of administration, Parkinson's disease, COVID-19, Investment, Risk, Hospital, Thyroid, Feeding tube, Subcutaneous tissue, Fungal infection, Infection, Diabetes, Research, Long-term care, Urbanization, Alzheimer's disease, Disease, Application, Pump, Arthritis, Incidence, Patient, Intramuscular injection, Failure, Death, Immune system, Endocrine system, Ageing, Endocrinology, Dementia, Growth, Prevalence, Medical device

The global home infusion therapy market in 2022 was valued at US$23.55 billion.

Key Points: 
  • The global home infusion therapy market in 2022 was valued at US$23.55 billion.
  • As chronic diseases become increasingly widespread worldwide, necessitating long-term treatment, home infusion therapy emerges as a more effective and efficient option for administration.
  • Therefore, surging prevalence of various chronic diseases is one of the main factors that would drive the demand for home infusion therapies in the forthcoming years.
  • Thus, the need for home infusion therapies is growing as the global population ages, which in turn, has augmented the growth of the global home infusion therapy market.

Global HbA1c Analyzers Market Analysis Report 2024-2031 - Leading Market Players Drive Growth Amidst Rising Prevalence of Diabetes and Technological Advancements - ResearchAndMarkets.com

Retrieved on: 
星期三, 四月 24, 2024
Health, Diabetes, International Diabetes Federation, Vaccination, Glycated hemoglobin, Disorder, Incidence, Diagnosis, COVID-19, Prevalence, Pharmaceutical industry

In this context, the demand for HbA1c analyzers is set to rise significantly, as hemoglobin measurement remains integral in diagnosing and managing diabetes.

Key Points: 
  • In this context, the demand for HbA1c analyzers is set to rise significantly, as hemoglobin measurement remains integral in diagnosing and managing diabetes.
  • The market is poised to benefit from the growing necessity for efficient diagnostic tools amidst the surge in diabetes cases globally.
  • Moreover, the utilization of HbA1c analyzers for pre-surgery glucose assessments is further fueling market growth, presenting lucrative opportunities for market players.
  • The HbA1c analyzers market presents a moderately competitive landscape, characterized by the presence of both domestic and foreign players, with global giants dominating the scene.

Global COVID-19 Vaccines Strategic Research Report 2024 - ResearchAndMarkets.com

Retrieved on: 
星期三, 四月 24, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, FDA, Cancer, Ageing, Vaccination, RNA, Partnership, US FDA, Vaccine, Messenger, COVID-19

The "COVID-19 Vaccines - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "COVID-19 Vaccines - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.
  • The global market for COVID-19 Vaccines, estimated at 6.4 Billion Doses in the year 2023, is projected to reach 4.2 Billion Doses by 2025.
  • The COVID-19 Vaccines market in the U.S. is estimated at 285 Million Doses in the year 2023.
  • mRNA vaccines are touted to provide better protection against newer variants, prompting discussions around the need for booster doses.